When starting Veozah (estradiol), what baseline and follow-up laboratory tests should be monitored?

Laboratory Monitoring for Veozah (Fezolinetant)

Yes, comprehensive hepatic laboratory monitoring is mandatory when starting Veozah due to significant hepatotoxicity risk, including baseline testing before initiation and frequent follow-up monitoring for the first 9 months of treatment. 111

Baseline Laboratory Requirements (Before Starting)

You must obtain the following hepatic function tests before prescribing the first dose 11:

• Serum ALT (alanine aminotransferase)
• Serum AST (aspartate aminotransferase)
• Serum alkaline phosphatase (ALP)
• Serum bilirubin (total and direct)

Do NOT Start Veozah If:

• ALT or AST ≥ 2 × ULN, OR
• Total bilirubin ≥ 2 × ULN 111

Follow-Up Monitoring Schedule

Mandatory hepatic laboratory testing at specific intervals 11:

• Monthly for the first 3 months (months 1,2, and 3)
• At 6 months
• At 9 months

This intensive monitoring protocol stems from both clinical trial data showing 2.3% of patients developed transaminase elevations >3 × ULN, and more importantly, postmarketing reports of drug-induced liver injury occurring within 40 days of starting Veozah 11. These postmarketing cases included elevations in ALT, AST, ALP, and total bilirubin with symptomatic presentations (fatigue, nausea, pruritus, jaundice, pale stools, dark urine).

When to Discontinue Based on Lab Results

Immediately stop Veozah if 11:

• Transaminase elevations > 5 × ULN, OR
• Transaminase elevations > 3 × ULN AND total bilirubin > 2 × ULN

If transaminase elevations > 3 × ULN occur: Perform more frequent hepatic laboratory monitoring until resolution 11.

Critical Clinical Pitfall

The FDA issued a boxed warning specifically for hepatotoxicity risk with Veozah 1. Unlike many medications where monitoring is suggested, this is a regulatory requirement with specific thresholds. Patients must also be counseled to discontinue immediately and seek medical attention (including hepatic labs) if they develop any signs of liver injury: new fatigue, decreased appetite, nausea, vomiting, itching, jaundice, pale stools, dark urine, or abdominal pain 11.

Note: The evidence provided about estradiol monitoring 23456789 is not relevant to Veozah (fezolinetant), which is a neurokinin 3 receptor antagonist for vasomotor symptoms, not an estrogen therapy. No estradiol level monitoring is required for Veozah.